Glucagon-like Peptide-1 Agonists - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The glucagon-like peptide-1 agonists market size is expected to grow from USD 46.18 billion in 2025 to USD 52.30 billion in 2026 and is forecast to reach USD 97.45 billion by 2031 at 13.26% CAGR over 2026-2031. This report is Segmented by Molecule (Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and More), Route of Administration (Daily Injectable, Weekly Injectable, and More), Indication (Type-2 Diabetes, Cardiovascular Risk Reduction, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Glucagon-like Peptide-1 Agonists Market Trends and Insights

Rising Prevalence of Type-2 Diabetes

International Diabetes Federation projections show diabetes cases climbing from 537 million in 2021 to 783 million by 2045, with 90% classified as type-2. Incidence is accelerating fastest across urbanizing Asia-Pacific economies, where lifestyle changes and aging populations converge. China alone documented a 12.4% adult prevalence in 2024, translating into more than 140 million individuals who often remain undertreated. The American Diabetes Association upgraded GLP-1 agonists to preferred second-line agents for patients with cardiovascular comorbidities in its 2024 Standards of Care, elevating the drug class above sulfonylureas and DPP-4 inhibitors for many clinical scenarios. As payers shift toward value-based models, the capacity of GLP-1 agonists to reduce microvascular and macrovascular complications strengthens formulary support, boosting the glucagon-like peptide-1 (GLP-1) agonists market well into the next decade.

Escalating Obesity Epidemic and Weight-Loss Approvals

World Health Organization data confirm that worldwide obesity prevalence nearly tripled between 1975 and 2024, affecting more than 890 million adults. Regulatory momentum is matching the epidemiologic urgency. Eli Lilly’s tirzepatide gained FDA clearance for chronic weight management in late 2023, followed by European approval in early 2024, breaking Wegovy’s early monopoly. In pivotal SURMOUNT-1 data, tirzepatide produced a 20.9% mean weight reduction, outperforming semaglutide’s 14.9% STEP-1 result. The FDA endorsement of semaglutide for obstructive sleep apnea in 2025 further widened the eligible population, encouraging Medicare Advantage plans to drop previous exclusions. Collectively these approvals have catalyzed a surge of obesity prescriptions that now form the single fastest-growing revenue stream inside the glucagon-like peptide-1 (GLP-1) agonists market.

High Therapy Cost and Limited Obesity Coverage

Annual U.S. wholesale acquisition costs range from USD 13,000 to USD 16,000, leaving uninsured and Medicare beneficiaries without diabetes exposed to full list prices. Only 38% of employer plans covered anti-obesity drugs in 2024; even then, prior authorizations and spending caps remain common. Novo Nordisk’s savings card caps Wegovy copays at USD 500 but does not address the 65-plus population excluded by statute. Across India, median household income of USD 2,400 renders branded GLP-1 therapy out of reach, steering demand toward forthcoming biosimilars. Thus pricing and coverage barriers temper overall GLP-1 agonists market expansion, particularly in obesity-only indications.

Other drivers and restraints analyzed in the detailed report include:

• Physician Shift to Once-Weekly GLP-1s
• Reimbursement and Guideline Expansion
• Gastro-Intestinal Side Effects and Discontinuation

Segment Analysis

Semaglutide generated 42.56% of 2025 revenue, anchoring the glucagon-like peptide-1 agonists market through its dual diabetes-obesity branding and extensive outcomes data. Tirzepatide’s 25.25% CAGR to 2031 reflects dual GIP/GLP-1 agonism that delivers larger HbA1c and weight reductions, bolstered by Lilly’s discounting strategy that undercuts Wegovy list prices. The GLP-1 agonists market size for tirzepatide could reach USD 38 billion by 2031 if current trial data readouts remain positive and capacity expansions stay on schedule. Dulaglutide and liraglutide are sliding into twilight phases as payer formularies migrate toward higher-efficacy weekly drugs. Meanwhile, retatrutide’s early-stage data suggest even greater weight-loss potential, indicating a pipeline that could further reshape molecule-level rankings within the GLP-1 agonists market.

Second-generation agents exenatide and lixisenatide now serve price-sensitive geographies or patients intolerant to stronger compounds. Biosimilar liraglutide filings in China and India may pressure pricing in value segments, but are unlikely to displace branded products in premium markets that demand proven outcomes data. As a result, the GLP-1 agonists industry remains a two-player race at the molecule level, with semaglutide and tirzepatide setting efficacy benchmarks that newer entrants must match or exceed.

Complete Report Scope:

• By Molecule
  • Exenatide
  • Liraglutide
  • Dulaglutide
  • Lixisenatide
  • Semaglutide
  • Tirzepatide
  • Others
• By Route of Administration
  • Daily Injectable
  • Weekly Injectable
  • Oral Small-Molecule
  • Long-acting Monthly (Pipeline)
• By Indication
  • Type-2 Diabetes
  • Obesity / Weight Management
  • Cardiovascular Risk Reduction
  • Other Emerging Indications
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America maintained 41.13% of 2025 revenue, supported by early approvals, high prevalence of obesity, and premium pricing. Adoption has now moved from specialist to primary-care settings, yet unit growth is plateauing as coverage widens and competition intensifies. Inflation Reduction Act price negotiations, effective 2027, will reduce average selling price but boost volume, providing net positive revenue stability for the glucagon-like peptide-1 (GLP-1) agonists market in the region.

Europe accounted for 28% of global sales in 2025. Centralized approvals speed multinational launches, but national cost-effectiveness reviews temper revenue per patient. Germany’s positive benefit rating for tirzepatide enabled higher negotiated pricing, whereas the United Kingdom’s narrower BMI eligibility dampens total addressable population. Continued reimbursement expansion tied to cardiovascular and renal outcomes is likely to drive mid-single-digit volume growth, preserving Europe as a solid, though mature, profit pool.

Asia-Pacific, recording the fastest 18.81% CAGR, is set to shift the global revenue mix as China, Japan, and India unlock large patient cohorts. China’s late-2024 tirzepatide approval and accompanying USD 1 billion local manufacturing commitment highlight strategic focus on domestic capacity that supports rapid volume ramp-up. Japan’s first-in-class obesity approval in early 2024 delivered strong initial uptake; local insurers are now reevaluating reimbursement ceilings, which should foster sustained growth. As regional governments confront soaring cardiometabolic disease costs, broader subsidization is expected, advancing the glucagon-like peptide-1 (GLP-1) agonists market toward leadership status in Asia-Pacific by the early 2030s.

List of Companies Covered in this Report:

• Amgen
• Amylink Bio
• Ascletis Pharma
• AstraZeneca
• Boehringer Ingelheim
• Eli Lilly and Company
• Gan & Lee Pharma
• Hanmi Pharmaceutical
• Hengrui Pharma
• Innovent Biologics
• Novo Nordisk
• Pfizer
• Roche
• Sanofi
• Structure Therapeutics
• Terns Pharmaceuticals
• Viking Therapeutics
• Zealand Pharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support